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A series of 15 @substituted 9-methylaaenines have been assessed as antagonists of 4-adenosine receptor- 
mediated stimulation of adenylate cyclase in membranes of human platelets and rat PC12 cells and of A,- 
adenosine receptor-mediated inhibition of adenylate cyclases in membranes of rat fat cells and as inhibitors 
of binding of N6-R-PHlphenylisopropyladenosine to A,-adenosine receptors in rat brain membranes. N6 
substitution can markedly increase the potency of 9-methyladenine at A, receptors, while having lesser ef- 
fects or even decreasing potency at 4 receptors. Effects of N6 substituents on adenosine receptor activity 
of the 9-methyladenines are reminiscent of effects of N6 substituents on activity of adenosine, suggesting 
that W substituted 9-methyladenines bind to adenosine receptors in the same orientation as do Wsubstitut- 
ed adenosines. N6-Cyclopentyl-9-methyladenine with K, values at the A, receptors of 1.3 PM (fat cells) and 
0.5 PM (brain) is at least lOO-fold more potent than 9-methyladenine (K, 100 RM, both receptors), while 
at the 4 receptors KB values of 5 PM (platelets) and 25 RM (PC12 cells) make it 5-fold more potent and 
equipotent, respectively, compared to 9-methyladenine (KB 24 ,uM, both receptors). WCyclopentyl and sev- 
eral other Walkyl and Wcycloalkyl analogs are selective for A, receptors while 9-methyladenine is the 
most 4 receptor selective antagonist. The P-R- and W-S(l-phenyl-2-propyl)-9-methyladenines, analo- 
gous to P-R- and &Y&phenylisopropyladenosines, exhibit stereoselectivity at both A, and 4 receptors. 
Marked differences in potency of certain M-substituted 9-methyladenines at the 4 receptors of human 
platelets and rat PC12 cells provide evidence that these are not identical receptors. 
Adenosine receptor; Adenylate cyclase 
1. INTRODUCTION 
Adenosine receptors have been divided into two 
subtypes, based on adenylate cyclase activity: Ai 
(Ri) receptors mediate inhibition and A2 (Ra) 
receptors mediate stimulation of adenylate cyclase 
activity (reviews [ 1,2]). Some N6-substituted 
adenosine analogs like N6-R-1-phenyl-2-propyl- 
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adenosine (R-PIA) have very high affinity for 
Ai-adenosine receptors, while 5’-N-ethylcarboxa- 
midoadenosine (NECA) is more potent than 
p-substituted analogs at A2 receptors. Alkylxan- 
thines, such as caffeine and theophylline, are the 
best known antagonists at adenosine receptors. 
Adenine was generally believed to have no effect 
on adenosine receptor-controlled systems. 
However, adenine is a specific, competitive an- 
tagonist of adenosine-induced cyclic AMP ac- 
cumulation in a human fibroblast cell line with a Kr 
of 200 pM [3]. Methylation of adenine at the 
9-position increases potency about 4-fold. A varie- 
ty of p-substituted 9-methyladenine derivatives 
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have now been prepared and tested in three 
adenylate cyclase-coupled adenosine receptor 
systems. For AZ-adenosine receptors human 
platelets and rat pheochromocytoma (PC12) cells 
and for Ai receptors rat fat cells were used. In ad- 
dition, the affinity for the Al-binding site for 
N6-R-1-[3H]phenylpropyladenosine ([3H]PIA) was 
determined in rat brain membranes. Certain of the 
p-substituted 9-methyladenines proved to be po- 
tent antagonists at adenosine receptors and some 
showed selectivity for either Ai or AZ receptors. 
2. MATERIALS AND METHODS 
The synthesis and the chemical properties of the 
adenine and hypoxanthine derivatives will be 
described elsewhere. [~u-~~P]ATP (40 Ci/mmol) 
was purchased from Amersham (Arlington 
Heights, IL). N6-R-l-[3H]Phenyl-2-propyladeno- 
sine (13H]PIA, 49.9 Ci/mmol) was purchased from 
New England Nuclear, Boston, MA. Other com- 
pounds used in this study were from standard 
soiirces as described [4]. 
Human platelet, rat pheochromocytoma (PC12) 
cell, rat fat cell and rat cerebral cortex membranes 
were prepared as in [4-61. Adenylate cyclase ac- 
tivity and binding of [3H]PIA to cerebral cortex 
membranes were determined essentially as de- 
scribed [4-61. 
KB values for the compounds were determined 
as in [4]. Briefly stated, concentration-response 
curves of NECA for the stimulation of adenylate 
cyclase of PC12 cell and platelet membranes and 
of R-PIA for the inhibition of isoproterenol- 
stimulated adenylate cyclase activity in fat cell 
membranes in the absence and presence of the 
adenine derivative were done using at least 7 con- 
centrations of the agonist. EGO and ICSO values 
for the agonists were obtained from the 
concentration-response curves by linear regression 
after logit-log transformation. KB values of the an- 
tagonists were calculated using the Schild equation 
KB = C/(CR - l), where C denotes the concentra- 
tion of the competitor and CR the ratio of the EGO 
and IGO values in the presence and absence, 
respectively, of the competitor. ICSO values of the 
compounds for inhibition of t3H]PIA binding to 
cerebral cortex membranes were transformed into 
Ki values as described [6]. 
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3. RESULTS 
3.1. AZ-Adenosine receptors 
The effects of adenine and adenine analogs on 
A2 receptor were studied in human platelets. In 
these cells, AZ receptor-mediated stimulation of 
adenylate cyclase results in an inhibition of ag- 
gregation [5,7]. 
Adenine (compound 1) itself does not affect 
basal adenylate cyclase activity (not shown), but 
antagonizes the NECA-induced stimulation of 
adenylate cyclase activity (table 1). However, 
adenine (1) is a very weak antagonist at A2 recep- 
tors of platelets, with a KB value of 760 PM (table 
1). Incorporation of a methyl group at the 
9-position of the adenine molecule results in a 
marked increase in potency. Thus, g-methyl- 
adenine (2) is 30-fold more potent than the adenine 
itself at AZ receptors of platelets. 
Substituents at the N6-position of g-methyl- 
adenine (2) markedly influence the antagonist 
potency at the platelet A2 receptor. The N6-cyclo- 
alkyl analogs (3,4,6) are more potent than g-me- 
thyladenine itself. 
Incorporation of an additional methyl group in- 
to N6-cyclopentyl-9-methyladenine (4) so as to 
yield a tertiary carbon at the N6-nitrogen reduces 
potency with N6-( 1-methylcyclopentyl)-g-methyl- 
adenine (5) being about lo-fold less potent than the 
parent cyclopentyl analog (4). The p-methyl 
analog (7) is much less potent than g-methyl- 
adenine at the platelet receptor, while the p-3- 
pentyl analog (8) is 2.5fold more potent. The 
Nd-phenyl analog (9) is equipotent to g-methyl- 
adenine. The presence of the or-rho-fluoro moiety 
in compound 10 increases potency 2-fold at the 
platelet A2 receptor. The N6-benzyl and p-2- 
phenethyl analogs (11,12) are less potent than 
9-methyladenine at the platelet receptors. p-2- 
(3,4,5 -Trimethoxyphenylethyl)-9-methyladenine 
(13) is as potent as 9-methyladenine. The hetero- 
aryl analog N6-2-(3-pyridylethyl)-9-methyladenine 
(14) is 4-fold less potent than 9-methyladenine, 
while another heteroaryl analog N6-2-(3-thienyl- 
ethyl)-9-methyladenine (15) is somewhat more po- 
tent. The A@- 1 -phenyl-Zpropyl derivatives are 
analogs containing a chiral carbon attached to the 
M-nitrogen: The R-isomer (16) is only about 
1.7-fold more potent than the S-isomer (17). The 
06-phenyl derivatives of 9-methylhypoxanthine 
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Table 1 
Potencies of 9-methyladenines and related compounds as antagonists at AZ- and Ai-adenosine receptors 
Compound Adenylate cyclase Binding 
KB *M) vs NECA stimulation KB tpM) VS Ki (JLM) VS 
PIA inhibition [‘H]PIA 
(Human platelet (Rat PC12 (Rat fat cell (Rat brain 
membranes) membranes) membranes) membranes) 
1. Adenine 
2. 9-Methyladenine (9-MA) 
M-substituted 9-methyladenines 
3. N6-Cyclobutyl-9-MA 
4. I@-Cyclopentyl-9-MA 
5. N6-Methylcyclopentyl-9-MA 
6. N6-Cyclohexyl-9-MA 
7. I@-Methyl-9-MA 
8. N6-3-Pentyl-9-MA 
9. N6-Phenyl-9-MA 
10. N6-2-Fluorophenyl-9-MA 
11. A@-Benzyl-9-MA 
12. N6-2-Phenethyl-9-MA 
13. N6-2-(3,4,5-Trimethoxyphenylethyl)- 
9-MA 
14. I@-2-(3-Pyridylethyl)-9-MA 
15. N6-2-(3-Thienylethyl)-9-MA 
16. N6-R-l-Phenyl-2-propyl-9-MA 
17. N6-S-l-Phenyl-2-propyl-9-MA 
06-substituted 9-methylhypoxanthines 
18. 06-Phenyl-9-methylhyppoxanthine 
(9-mH) 
19. 06-(2-Fluorophenyl)-9-MH 
20. 06-(3-Fluorophenyl)-9-MH 
21. 06-(4-Fluorophenyl)-9-MH 
760 (610-950) 
24 (21-27) 
5.5 (2.4-13) 
4.9 (4.5-5.4) 
45 (37-53) 
7.4 (2.2-25) 
150 (120-200) 
11 (9.4-12) 
21 (4.5-98) 
11 (6.6-20) 
57 (37-89) 
170 (140-220) 
23 (21-25) 
92 (80-107) 
14 (4.4-45) 
13 (8-22) 
23 (18-28) 
570 (330990) 
24 (19-30) 
23 (14-39) 
25 (17-36) 
56 (37-85) 
21 (12-38) 
130 (80-210) 
53 (35-78) 
107 (60-190) 
29 (24-35) 
100 (77-130) 
120 (90-160) 
40 (38-42) 
117 (83-147) 
25 (4.9-102) 
25 (19-33) 
74 (43-128) 
>lOOO 
>lOOO 
>lOOO 
>lOOO 
>lOOO 
112 (79-160) 
0.89 (0.76-1.1) 1.2 (1.1-1.5) 
1.3 (0.88-2.0) 0.54 (0.45-0.67) 
9.0 (5.6-14.2) 2.5 (1.9-3.2) 
0.65 (0.44-O.%) 0.94 (0.40-2.2) 
220 (150-310) > 100 (42%) 
7.6 (6.4-9.1) 3.3 (2.2-5.1) 
10 (5.5-18) 25 (13-49) 
17 (11-27) 8.5 (7.1-10.2) 
49 (32-75) 17 (7.5-36) 
>300 > 100 (12%) 
122 (93-159) 
96 (70-130) 
24 (20-30) 
7.2 (5.5-9.5) 
23 (11.4-47) 
400 (370-470) 
400 (310-510) 
>loOO 
560 (470-680) 
> 100 (28%) 
106 (87-129) 
> 100 (43010) 
41 (32-54) 
20 (14-27) 
2.5 (1.9-3.4) 
10 (6-17) 
> 100 (10%) 
> 100 (11%) 
> 100 (16%) 
> 100 (20%) 
Ka and Ki values were calculated as described in section 2 and are geometric means with 95% confidence limits from 
three experiments. In some cases, the inhibition of binding at the highest concentration tested is given in parentheses 
following that concentration 
(18-21) are very weak or inactive as inhibitors of 
NECA-induced stimulation of adenylate cyclase 
activity of human platelet membranes. 
The potencies of the adenine derivatives were 
determined in a similar mamier for A2 receptors of 
rat pheochromocytoma (PC12) cells [4,8,9], using 
antagonism of the NECA-induced stimulation of 
adenylate cyclase activity of the PC12 cell mem- 
branes to assess antagonist potencies (table 1). 
While there are similarities, there are also some 
notable differences in the structure-activity rela- 
tionship for the adenines at A2 receptors of 
platelets and PC12 cells. 
As was the case for the platelet system, adenine 
(1) is a very weak antagonist of the NECA- 
stimulated adenylate cyclase in PC12 cell mem- 
branes with a KB of 570 /IM. 9-Methyladenine (2) 
is equally potent at A2 receptors of human platelets 
and rat PC12 cells with a & of about 25 ,uM in 
both cases. In contrast to the results with platelets, 
incorporation of N6 substituents into g-methyl- 
adenine does not in any case increase the potency 
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of the 9-methyladenine at the AZ receptors of PC12 
cells: 
Potencies of all of the hP-substituted 
9-methyladenines at AZ receptors of PC12 cells are 
either the same as or lower than that of the parent 
compound. 
In certain cases, namely the N6-cyclopentyl (4), 
N6-3-pentyl (8) and N6-phenyl (9) analogs, the 
analog is 5-fold more potent at the platelet A2 
receptor than at the PC12 A2 receptor. In no case 
is the p-substituted 9-methyladenine l ss potent at 
the platelet A2 receptor than at the PC12 A2 recep- 
tor. Incorporation of an additional methyl to yield 
the tertiary analog N6-l-methylcyclopentyl-9- 
methyladenine (5) reduces potency only 2-fold in 
PC12 cells, while decreasing potency nearly 
lo-fold in platelets. 
The R- and S-isomers of ti-l-phenyl-2-propyl- 
9-methyladenine (16,17) exhibit an R/S ratio of 3 
in PC12 cells compared to a ratio of 1.7 in 
platelets. The 06-phenyl-9-methylhypoxanthines 
(18-21) are nearly inactive in both cell types. 
3.2. AI-Adenosine receptors 
Rat fat cells were used for evaluation of 
structure-activity relationships of adenine deriva- 
tives at adenylate cyclase-coupled Ai-adenosine 
receptors. In these cells, adenosine analogs cause 
an inhibition of adenylate cyclase activity and 
lipolysis [lo]. 
Adenine (1) itself does not affect R-PIA-induced 
inhibition of fat cell adenylate cyclase activity 
(table 1). 9-Methyladenine (2) antagonizes the ef- 
fect of R-PIA with a Kn of 112pM and is, 
therefore, about 5-fold less potent at Ar receptors 
than at AZ receptors. Incorporation of cycloalkyl 
or alkyl substituents into the @-position of 
9-methyladenine (2) can markedly increase the an- 
tagonistic potency at the fat cell Al receptor. Thus, 
the N6-cycloalkyl-9-methyladenines (3,4,6) are 
about lOO-fold more potent than the parent com- 
pound 9-methyladenine and N6-3-pentyl-9-methyl- 
adenine (8) is about 15-fold more potent than the 
parent compound at Ai receptors of fat cells. 
N6-Methylcyclopentyl-9-methyladenine (5) is 
about cl-fold less potent than the N6-cyclopentyl 
analog (4). The p-methyl analog (7) is 2-fold less 
potent than 9-methyladenine. The two N6-phenyl 
analogs (9,lO) are 6-lo-fold more potent than 
9-methyladenine in the fat cell, while the N6-benzyl 
206 
(11) analog is only 2-fold more potent. The 
N6-2-phenethyl(12) analog is much less potent. Of 
the phenethyl (12,13) and heteroarylethyl (14,lS) 
analogs only the N6-2-(3-thienylethyl)-9-methyl- 
adenine is more potent than 9-methyladenine itself 
in the fat cell. The R- and S-isomers of N6-l-phe- 
nyl-2-propyl-9-methyladenine (16,17) exhibit a 
3-fold stereoselectivity in fat cells, which is the 
same as in the PC12 cells. However, in contrast to 
PC12 cells, these R- and S-isomers (16,17) are 
about 16- and 5-fold, respectively, more potent 
than the parent compound at Ai receptors of fat 
cells. The 06-phenyl-9-methylhypoxanthines 
(18-21) are very weak or inactive as antagonists in 
fat cell membranes. 
Similar results were obtained when the Ki values 
of the adenine derivatives for inhibition of 
[3H]PIA binding to rat cerebral cortex membranes 
were determined (table 1). The low potency of 
adenine (1) is commensurate with the results from 
the fat cell adenylate cyclase assay. 9-Methyl- 
adenine (2) is equally potent at AI receptors of fat 
cells and cerebral cortex. The Ki values of the 
N6-substituted 9-methyladenine derivatives for in- 
hibition of radioligand binding in brain mem- 
branes are generally 2- and 3-fold lower than the 
corresponding KB values from the fat cell 
adenylate cyclase. As in the case with fat cells, 
N6-cyclopentyl-9-methyladenine (4)is about 5-fold 
more potent than the N6-methylcyclopentyl analog 
(5). The 2-phenethyl (12,13) analogs are very weak 
antagonists of [3H]PIA binding in rat brain mem- 
branes as expected from results with fat cell 
adenylate cyclase. N6-R-l-Phenyl-2-propyl-9- 
methyladenine (16) has a Ki of 2.5 ,uM vs [3H]PIA 
binding and is, therefore, 4-fold more potent than 
the S-isomer (17). The 06-phenyl-9-methylhypox- 
anthine derivatives (18-21) only marginally inhibit 
[3H]PIA binding. 
4. DISCUSSION 
Xanthines, the major structural class of an- 
tagonists for adenosine receptors, have a planar 
heterocyclic ring system analogous to the 
heterocyclic purine (adenine) ring of adenosine. It 
has been proposed that the site in adenosine recep- 
tors that interacts with the adenine ring of 
adenosine also interacts with the xanthine ring of 
such adenosine antagonists as theophylline and 
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caffeine [2]. A variety of other compounds con- 
taining a planar heterocyclic ring have antagonistic 
activity at adenosine receptors. These include 
pyrazolopyrimidines [ 111, pyrazolopyridines [ 12, 
131, mesoionic xanthine analogs [ 141, benzo- 
pteridines [3], and 9-methyladenine [3]. The last 
hefi?rocycle 9-methyladenine, because of the identi- 
ty of the heterocyclic ring with that of adenosine, 
seems even more likely than other heterocycles to 
bind at the same ‘heterocycle’ site as do the 
adenosines. The present study was designed to test 
the premise that, as in the case of adenosine, I@ 
substituents on 9-methyladenine would alter activi- 
ty of the 9-methyladenines in the same way as 
N6-substituents alter the activity of adenosines. 
The topography of binding site for N6 substituents 
in both Ai- and AZ-adenosine receptors has been 
extensively investigated (see [9,16] and references 
therein). The binding site for N6 substituents dif- 
fers significantly for Al receptors compared to AZ 
receptors. At the Al receptors, N6 substituents can 
markedly enhance activity. The stereoselectivity 
for compounds such as R- and S-PIA that contain 
chiral N6 substituents is a well-known charac- 
teristic of A1 receptors. At the A2 receptors, most 
I@ substituents reduce activity of adenosine and 
stereoselectivity is less pronounced than at A1 
receptors. 
Certain N6 substituents do markedly enhance ac- 
tivity of 9-methyladenine at Ai receptors. The 
N6-cycloalkyl-9-methyladenines (3,4,6) are the 
most potent of p-substituted 9-methyladenines at 
Ai receptors being SO-200-fold more potent than 
9-methyladenine. Similarly, N6-cycloalkyladeno- 
sines are among the most potent @-substituted 
adenosines of Ai receptors [9]. Introduction of an 
additional methyl to N6-cyclopentylmethyladenine 
(4) to yield N6-1-methylcyclopentyl-9-methyl- 
adenine (5) reduces activity at Ai receptors. 
Similarly, activity of the N6-(l-methylcyclopen- 
tyl)adenosine at Ai receptors is reduced compared 
to N6-cyclopentyladenosine [9]. The only N6-alkyl 
or N6-cycloalkyl substituent hat reduces activity 
of 9-methyladenines at Ai receptors is methyl, 
reminiscent of the low activity of p-methyl- 
adenosine at Al receptors [9]. The modest activity 
of N6-benzyl-9-methyladenine (11) is also conso- 
nant with the low activity of N6-benzyladenosine at 
Ai receptors 191. Somewhat surprising was the low 
activity of N6-2-phenethyl-9-methyladenine (12), 
since the corresponding adenosine analog exhibits 
moderate activity at Ai receptors [9]. The R- and 
S-enantiomers of N6-( 1 -phenyl-2-propyl)-9-me- 
thyladenine, analogous to R- and S-PIA, exhibit 
stereoselectivity at Ar receptors with the R-enan- 
tiomer being 3-4-fold more potent than the 
S-enantiomer. Unlike the diasteromers R- and 
S-PIA, these analogs are true enantiomers, since 
the other chiral centers of the ribose moiety are 
absent. It should be noted that the stereoselectivity 
of the 9-methyladenine analogs at A1 receptors 
(table 1) is much less than that of R- and S-PIA at 
Ai receptors [9]. 
The results indicate that 9-methyladenines show 
effects of N6 substituents on activity at Ai recep- 
tors similar to, but not identical with the effects of 
N6 substituents on agonist activity of adenosines at 
Ai receptors. The near lack of activity of the four 
06-phenyl-substituted 9-methylhypoxanthines is 
reminiscent of the inactivity of purine ribosides 
containing oxygen or sulfur in place of nitrogen at 
the 6-position at adenosine receptors [ 151. 
At A2 receptors, I@ substituents have much 
smaller effects on activity of 9-methyladenine than 
was the case of A1 receptors. Indeed, many substi- 
tuents have no effect or reduce activity. The two 
A2 receptors do not appear identical in terms of in- 
teraction with the p-substituted 9-methylade- 
nines. Whether such differences are related to 
species or tissue are unknown. Certainly, brain Ai 
receptors differ markedly in agonist/antagonist ac- 
tivity in different species [16]. At the A2 receptor 
of human platelets only the cycloalkyl-, 3-pentyl-, 
2-fluorophenyl-, 2-(3-thienylethyl)- and R-l- 
phenyl-2-propyl- substituents enhance activity. 
Certain p-substituted adenosines corresponding 
in structure to the p-substituted 9-methyladenines 
have been investigated as agonists at platelet A2 
receptors [9]. There was only a modest range of 
potency with the N6-cyclobutyl-, N6-cyclohexyl-, 
N6-2-(3-thienylethyl)- and N6-benzyladenosines 
and R-PIA being the more potent of the 
@-substituted adenosines. Thus, the results with 
p-substituted 9-methyladenines at platelet AZ 
receptors would not have been predicted from the 
effects in the analogous adenosines. At the AZ 
receptors of PC12 cells, none of the i@ substitu- 
ents increased activity relative to 9-methyladenine 
itself. Indeed, certain substituents decreased activi- 
ty. Again, these effects would not have been 
207 
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predicted from the agonist activity of the 
analogous N6-substituted adenosines at A2 recep- 
tors of PC12 cells [9]: As for the platelet A2 recep- 
tor there was not a wide range of potencies for the 
adenosines at PC12 receptors with the 
N6-cyclobutyl-, R-PIA, N6-2-phenethyl-, N6-cyclo- 
hexyl-, N6-2-(3_pyridylethyl)- and N6-2-(3,4,5tri- 
methoxyphenyiethyl) analogs being the more 
potent of the series. Thus, the effects of N6 
substitution on activity of 9-methyladenines and 
adenosines at A2 receptors are not identical, 
perhaps reflecting the lack of major positive con- 
tributions of such substituents to activity at A2 
receptors. It is of interest hat data on both the an- 
tagonist series of p-substituted adenine (table 1) 
and the agonist series of M-substituted adenosines 
[9] provide evidence for the lack of identity of AZ 
receptors in platelets and PC12 cells. The 
06-phenyl-9-methylhypoxanthines are inactive or 
nearly so at the A2 receptors, as is the case for 
6-phenoxypurine riboside at coronary A2 receptors 
]171. 
Certain of the N6-substituted 9-methyladenines 
are somewhat selective (5-lo-fold) for Ai recep- 
tors, in particular N6-cyclobutyl, cyclopentyl-l- 
methylcyclopentyl- and cyclohexyl analogs, while 
9-methyladenine and N6-2-(3,4,5-trimethoxy- 
phenylethyl)-9-methyladenine exhibit a 3-4-fold 
selectivity for A2 receptors. Further investigation 
of this new class of adenosine receptor antagonists 
both in vitro and in vivo will be required to 
establish their usefulness in definition and eluci- 
dation of functions of adenosine receptors. 
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